HARROW HEALTH, INC.

NASHVILLE, TN How do I update this listing?

Harrow Health is based out of Nashville. Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of non-invasive topically delivered medications. The company's lead topical drug candidate, Ketotransdel, utilizes its proprietary Transdel cream formulation to facilitate the passage of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the epidermis and into underlying tissues. Ketotransdel provides an alternative to the oral administration of cyclooxygenase-2 selective NSAIDs (COX-2 inhibitors) and non-selective NSAIDs. It has completed a Phase 1/2 trial for treating soft tissue pain and soreness in a delayed onset muscle soreness model with Ketotransdel. Transdel Pharmaceuticals also investigates other drug candidates and treatments for transdermal delivery using Transdel technology, including anesthetics, human hormone replacement, and anti-nausea medications. The company was founded in 1998 and is headquartered in La Jolla, California.Whalewisdom has at least 1 13D filings, and 80 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2016-12-30. The notice included securities offered of Equity,Option, Warrant or Other Right to Acquire Another Security

Create Email Alert

Contact Info

harrow health, inc.
102 WOODMONT BLVD
NASHVILLE TN    37215

Business Phone: 615.733.4731
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS
Current 13D/G Holdings
Stock Sector Shares Held Market Value Rank Source Source Date
Eton Pharmaceuticals Inc (ETON) HEALTH CARE 3,500,000 22,120,000.00 1 13D 2018-11-15

Active Schedule 13D and 13G events

Sign in to see

Form 4 - Recent Insider Transactions

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2016-12-30 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 10,068,740 10,068,740 0
2015-01-15 D PHARMACEUTICALS Equity,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 818,750 500,000 318,750
2012-05-03 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security 7,946,180 7,946,180 0
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
ANDREW BOLL subscription required
    EXECUTIVE OFFICER
ANTHONY PRINCIPI subscription required
    DIRECTOR
BALBIR BRAR subscription required
    EXECUTIVE OFFICER DIRECTOR
JEFFREY ABRAMS subscription required
    DIRECTOR
JOACHIM SCHUPP subscription required
    EXECUTIVE OFFICER
MARK BAUM subscription required
    EXECUTIVE OFFICER DIRECTOR
PAUL FINNEGAN subscription required
    DIRECTOR
RICHARD L. LINDSTROM subscription required
    DIRECTOR
ROBERT KAMMER subscription required
    DIRECTOR
STEPHEN G. AUSTIN subscription required
    DIRECTOR
WILLIAM H. NELSON subscription required
    DIRECTOR

Elevate your investments